GREENFIELD, Ind., Jan. 18, 2018 /PRNewswire/ -- Elanco Animal
Health, a division of Eli Lilly and Company (NYSE: LLY), received
two of the top honors in both food and companion animal innovation
from Animal Pharm, a leading industry publication. During the
2017 award cycle, Galliprant (grapiprant tablets) was named
Animal Pharm's Best Companion Animal Product and Clynav took
top honors as best food animal product.
"Elanco has been working to bring innovation to our customers
and the animals they care for since 1954," said Aaron Schacht, Vice President of global research
and development at Elanco."To be recognized as a leading innovator
in both the veterinarian's office and by producers is deeply
gratifying, and a testament to our commitment to animal
health. These awards also recognize that Elanco can leverage
internal and external innovation approaches to introduce new
products."
Designed to honor achievements within the animal health sector
during a calendar year, Animal Pharm's awards are decided by
an independent panel of industry experts.
"The judging panel commended Elanco's products as being
first-in-class. Personally, I think both of these products
highlight two areas ripe for exciting growth in the animal health
space," said Joseph Harvey, editor
of Animal Pharm. "Firstly, Galliprant is shaking up the
competition in the canine osteoarthritis pain space. Secondly,
Clynav showcases Elanco's innovation capabilities in the
aquaculture health market."
About Galliprant
Galliprant, which provides targeted pain control from the
earliest diagnosed stages of canine osteoarthritis, was made
commercially available to veterinarians in January 2017 through a license and collaboration
agreement with Aratana Therapeutics, Inc. Galliprant is the
first piprant (a non-COX-inhibiting prostaglandin receptor
antagonist) approved for use in veterinary medicine. As a targeted
tool for the management of pain and inflammation
associated with canine osteoarthritis (OA), it represents the
evolution of canine anti-inflammatory drugs by specifically
blocking the prostaglandin E2 EP4 receptor, which is the
primary mediator of OA pain and
inflammation.1
About Clynav
Clynav, a solution for injection, was approved for use by the
European Commission in June 2017 for
the active immunisation of Atlantic salmon to reduce impaired daily
weight gain, and reduce mortality, and cardiac, pancreatic and
skeletal muscle lesions caused by pancreas disease following
infection with salmonid alphavirus subtype 3 (SAV3).It was
subsequently granted a marketing authorization in Norway in July
2017 in accordance with the terms of the Centralized
Procedure.
The 2017 awards are Elanco's fourth and fifth Animal
Pharm awards. The company has previously won Best Company North
America 2014 and Best Product Portfolio 2015. Elanco's President,
Jeff Simmons, has also previously
been honored for his role as an inspirational leader.
Galliprant Important Safety Information
Not for
use in humans. For use in dogs only. Keep this and all medications
out of reach of children and pets. Store out of reach of dogs and
other pets in a secured location in order to prevent accidental
ingestion or overdose. Do not use in dogs that have a
hypersensitivity to grapiprant. If Galliprant is used long term,
appropriate monitoring is recommended. Concomitant use of
Galliprant with other anti-inflammatory drugs, such as
COX-inhibiting NSAIDs or corticosteroids, should be avoided.
Concurrent use with other anti-inflammatory drugs or protein-bound
drugs has not been studied. The safe use of Galliprant has not been
evaluated in dogs younger than 9 months of age and less than 8 lbs.
(3.6 kg), dogs used for breeding, pregnant or lactating dogs, or
dogs with cardiac disease. The most common adverse reactions were
vomiting, diarrhea, decreased appetite, and lethargy. For full
prescribing information call 1-888-545-5973.
About Elanco
Elanco provides comprehensive products
and knowledge services to improve animal health and food-animal
production in more than 70 countries around the world. We value
innovation, both in scientific research and daily operations, and
strive to cultivate a collaborative work environment for more than
6,500 employees worldwide. Together with our customers, we are
committed to raising awareness about global food security, and
celebrating and supporting the human-animal bond. Founded in 1954,
Elanco is a division of Eli Lilly and Company. Our worldwide
headquarters and research facilities are located in Greenfield, Indiana. Visit us at Elanco.com
and EnoughMovement.com.
GCAAFFGLP00002
1 Kirkby Shaw, K,
Rausch-Derra, LC, and Rhodes, L. 2015. "Grapiprant: an EP4
prostaglandin receptor antagonist and novel therapy for pain and
inflammation." Veterinary Medicine and Science: 1-7.
PDF - https://mma.prnewswire.com/media/630555/Elanco_Animal_Health.pdf
View original content with
multimedia:http://www.prnewswire.com/news-releases/elanco-innovations-named-best-products-for-2017-300584719.html
SOURCE Elanco Animal Health